1.
Clinical application of platelet-rich fibrin to enhance dental implant stability: A systematic review and meta-analysis
Guan S, Xiao T, Bai J, Ning C, Zhang X, Yang L, Li X
Heliyon. 2023;9(2):e13196
Abstract
OBJECTIVE To investigate the effect of platelet-rich fibrin application on implant stability. STUDY DESIGN Five databases, namely, PubMed, Embase, Web of Science, Wiley, and China National Knowledge Infrastructure, were searched for reports published up to November 20, 2022. Randomized controlled trials (RCT), including parallel RCTs and split-mouth RCTs, with at least 10 patients/sites were considered for inclusion. RESULTS After screening based on the inclusion criteria, ten RCTs were included. Low heterogeneity was observed in study characteristics, outcome variables, and estimation scales (I(2) = 27.2%, P = 0.19). The qualitative and meta-analysis results showed that PRF increased the effect of implant stabilizers after implant surgery. CONCLUSIONS The results of the present systematic review and meta-analysis suggest that PRF can increase implant stability after implant surgery. PRF may also have a role in accelerating bone healing and tends to promote new bone formation at the implant site.
2.
Low-dose, Early Fresh frozen plasma Transfusion therapy after severe trauma brain injury: a clinical, prospective, randomized, controlled study (LEFT)
Zhang LM, Li R, Sun WB, Wang XP, Qi MM, Bai Y, Bai J, Zheng W
World neurosurgery. 2019
Abstract
BACKGROUND To investigate the role of Low-dose, Early Fresh frozen plasma Transfusion (LEFT) therapy in preventing peri-operative coagulopathy and improving long-term outcome after severe traumatic brain injury (TBI). METHODS A prospected, single-centre, parallel-group, randomized trial was designed. Patients with severe TBI were eligible. We used a computer-generated randomization list, and closed opaque envelopes to randomly allocate patients to treatment with FFP (5mL/kg of body weight) as LEFT treatment or normal saline (5mL/kg of body weight) as no LEFT treatment once admitting to operation room. RESULTS Between 1 January 2018 and 31 November 2018, 63 patients were included and randomly allocated to LEFT (n=28) and NO LEFT (n=35) groups. 20 patients in the LEFT group and 32 patients in the NO LEFT group were included in the final interim analysis. The study was terminated early for futility and safety reasons because of the high proportion of patients (7 of 20, 35.0 %) in the LEFT group developing new delayed traumatic intracranial hematoma (DTICH) after surgery as compared with 3 of 32 in the NO LEFT group (9.4 %) (relative risk, 5.205; 95% CI, 1.159 to 23.384; P=0.023). Demographic characteristics and indexes of severity of brain injury were similar at baseline. CONCLUSION Low-dose, early fresh frozen plasma transfusion therapy was associated with higher incidence of DTICH than normal FFP transfusion in patients with severe TBI. A restricted FFP transfusion protocol, in the right clinical setting, may be more appropriate in patients with TBIs. (Current Controlled Trials number, ChiCTR-INR-17013901).
3.
Effect of allogeneic blood transfusion on levels of IL-6 and sIL-R2 in peripheral blood of children with acute lymphocytic leukemia
Zhao H, Zhou H, Cao Q, Wang C, Bai J, Lv P, Zhao F
Oncology Letters. 2018;16((1)):849-852.
-
-
Free full text
-
Abstract
Effect of allogeneic blood transfusion on the expression of interleukin-6 (IL-6) and soluble interleukin-2 receptor (sIL-2R) in peripheral blood of children with acute lymphoblastic leukemia (ALL) was investigated. A total of 91 ALL children admitted to Nanfang Hospital from June 2014 to January 2017 were selected as the study group. Patients were randomly divided into allogeneic blood transfusion group (n=38) and non-transfusion group (n=53). In addition, a total of 64 healthy children were also selected from June 2014 to January 2017 as the control group. Patients in allogeneic blood transfusion group were transfused with red blood cell suspension and machine-collected platelets, while patients in non-transfusion group were not treated with blood transfusion. Peripheral venous blood was collected before and at 4, 8 and 12 weeks after blood transfusion to prepare serum. Serum IL-6 and sIL-2R levels were measured by enzyme-linked immunosorbent assay (ELISA). Before transfusion, serum levels of IL-6 and sIL-2R were significantly lower in the study group than those in control group (p<0.05), and no significant differences in serum levels of IL-6 and sIL-2R were found between the allogeneic blood transfusion and non-transfusion group. After transfusion, serum levels of IL-6 and sIL-2R were stable for 12 weeks in the non-transfusion group, while IL-6 and sIL-2R levels were significantly increased in the allogeneic blood transfusion group. The results showed that serum level of IL-6 and sIL-2R was increased in ALL patients with allogeneic blood transfusion, which resulted in reduced antibody production and decreased cellular immunity. The patients had low immunity, and attention should be paid on the pathogen infection prevention.